Tagged with Opinion,

Opinion Pierre Meulien of the Innovative Medicines Initiative (IMI) discusses the potential impact that new technological innovations will have on the drug development process.   A more technologically integrated approach is required that looks more holistically at the patient as an individual Whether we call it “Personalised”, “Precision”, “Stratified”, or “Tailored”, the age…

Europe From her vantage point as associate vice president for MSD’s Central & Eastern Europe (CEE) cluster, Gabriele Grom outlines the disparity that still exists in terms of access to cancer treatments across Europe and what must be done to bridge this gap.   Despite the existence of innovative treatments, cancer…

AI Axel Schumacher highlights the vital importance of AI and blockchain for the future success of pharmaceutical companies, the significant knowledge gap that currently exists within Big Pharma, and why, therefore, now is the time for these firms to invest in AI and blockchain start-ups.   While almost everyone is talking…

USA Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to ensure the safety of rare disease patients – many of them children – who are using CBD products for their…

AI Digital marketing expert Buck Dossey expounds the importance of soliciting user data to improve patient experiences and the ways in which AI can be utilised within this process.   Companies should start by thinking of ways to leverage unified data sets and digital access points to create and deliver connected,…

Opinion Aditya Bhattacharji examines whether current healthcare models are truly fit for purpose and how healthcare is becoming a more politicised issue globally.   Globally, the healthcare sector is entering a lengthy period of heightened introspection. That process has been turbocharged by the resurgence of healthcare as a dominant social and…

Canada Canada is the only developed country with a universal healthcare system that does not provide universal coverage of prescription drugs. With a new national ‘pharmacare’ program being proposed to remedy this situation, Pamela Fralick of Innovative Medicines Canada outlines the strengths and weaknesses of the proposal on the table and…

Opinion David H. Crean, managing director for Objective Capital Partners, highlights the progress that has been made over the past year in investments in medical cannabis and the outlook for 2019.     Due to ongoing research and studies, positive results are leading countries to reconsider the cannabis plant The cannabis industry…

Opinion Cerecin’s Charles Stacey looks at the large unmet medical need in diseases of the central nervous system (CNS), the looming socioeconomic burden that these diseases represent, and the innovative solutions needed to counter it.   45 percent of the patient population in neurology remains unserved – they either have no…

Opinion An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO of Betterpath Health and now SVP and chief product officer at Hu-manity.co.   Now that we have all this data,…

USA Jessica Federer, advisor at Hugo Health and one of the speakers at the upcoming FT US Pharma and Biotech Summit, discusses some of the key trends shaping the US pharma market, her predictions for the next year, and recent developments for women in pharma.   Recently, we have witnessed some…

USA Paul Bleicher, CEO at OptumLabs, and one of the speakers at the FT US Pharma & Biotech Summit on May 14, shares insights on the benefits we will see AI bring to pharma companies and patients in the short and long term, as well as use cases for the technology.…